Specifically, SST2 and SST5 are considered the main pharmacological targets of somatostatin analogs (SSAs) octreotide and pasireotide in the treatment of acromegaly caused by GH-secreting pituitary tumors (22). The gene discussed is SSTR5; the disease is pituitary tumor.